(This Section may contain text from a Public Act with a delayed effective date)

Notwithstanding any other provision of law, a health insurance issuer or a contracted utilization review organization may not require a prior authorization for drug therapies approved by the U.S. Food and Drug Administration for the treatment of hereditary bleeding disorders more frequently than every 6 months or the length of time the prescription for that dosage remains valid, whichever period is shorter.

(Source: P.A. 103-659, eff. 1-1-26; 104-417, eff. 8-15-25.)